CRISPR Therapeutics AG
CRSP: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| $851.00 | Hjg | Jxlfhblf |
CRISPR Therapeutics’ Pipeline Continues to Make Progress; Maintaining $119 FVE, Shares Undervalued
/s3.amazonaws.com/arc-authors/morningstar/ca9ef979-0207-4e37-b392-91618ebc1841.jpg)
CRISPR Therapeutics reported second-quarter results in line with our expectations, and its pipeline candidates are continuing to progress in development. We maintain our fair value estimate of $119 per share and view the stock as undervalued, currently trading in 4-star territory. As a clinical-stage biotech company, CRISPR Therapeutics provides long-term investors with pure play exposure to novel gene editing technology to treat severe genetic diseases.